EDEN PRAIRIE, Minn., July 11, 2017 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ:CHFS) announced today that Laurent Duhoux joined the Company as International Business Development consultant. In this capacity, Mr. Duhoux will be responsible for European and Asian market expansion for the Aquadex FlexFlow system.
“I am very excited to welcome Laurent to CHF Solutions. His deep experience and proven track record of success is opportune at this exciting time in our evolving future, as we continue to grow our ultrafiltration business,” said John Erb, Chairman and Chief Executive Officer of CHF Solutions. “Laurent brings 25 years of proven marketing leadership and medical device expertise in international product launches, marketing program management, KOL development and developing health economic strategies and will be invaluable as we re-launch our product internationally.”
Prior to his engagement with CHF Solutions, Mr. Duhoux spent 7 years with Edwards Life Sciences in several senior marketing positions, launching new products and building the European market for those products. Prior to his Edwards experience, Mr. Duhoux spent 18 years with Gambro Renal Products, with the last four years as Vice President of the Intensive Care Business. Mr. Duhoux was the senior marketing executive and championed the analysis and recommendation leading to Gambro’s decision in 2010 to acquire the company that originally developed the Aquadex FlexFlow system. Mr. Duhoux is fluent in English, French, German, Spanish and Portuguese. He holds a Master Degree in Biomedical Engineering from the University of Lyon, France.
About CHF Solutions
CHF Solutions, Inc. (NASDAQ:CHFS) is an early-stage medical device company focused on commercializing the Aquadex FlexFlow system for Aquapheresis® therapy. The Aquadex FlexFlow system, is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company's objective is to improve the quality of life for patients with heart failure and related conditions. CHF Solutions is a Delaware corporation headquartered in Minneapolis with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the NASDAQ Capital Market since February 2012.
Forward-Looking Statements
Certain statements in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding European and Asian markets expansion and re-launching products internationally. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our recently announced strategic realignment, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. CHF Solutions does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.